-

Tod Reed Joins Lynch Regenerative Medicine as Strategic Advisor

Reed is former Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics at Abbvie

FRANKLIN, Tenn.--(BUSINESS WIRE)--Tod Reed will join Lynch Regenerative Medicine, LLC (LRM) as a Senior Strategic Advisor. Reed recently retired as the Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics, an Abbvie company.

Reed brings 37 years of experience with Allergan to the LRM team, including more than 20 years in aesthetic and regenerative medicine. During his tenure at Allergan Aesthetics, Reed was responsible for helping build the largest sales organization in U.S. medical aesthetics while helping launch iconic brands such as Botox Cosmetic®, Juvederm®, and many other products in skin care, body contouring and aesthetic surgery. He was also responsible in the U.S. market for the renowned practice consulting group, strategic accounts, sales force operations and the sales training department.

“At LRM, we are building a leading regenerative medicine and aesthetics company based on the most proven and trusted science in the industry, combined with the some of the most experienced, talented and trusted people in aesthetics and regenerative medicine,” said Dr. Samuel Lynch, founder and CEO of LRM. “Tod’s leadership at Allergan Aesthetics helped build it into the world’s largest aesthetic medicine company. We welcome him to the LRM team, where we strive every day to bring the best products together with the best people to advance the regenerative medicine and aesthetics fields.”

“I am humbled and excited to join Lynch Regenerative Medicine as a strategic advisor,” said Reed. “The team is excellent, with years of industry experience, and the product line both current and in the future will bring needed enhancements to the growing markets for aesthetics and regenerative medicine.”

LRM’s first product to improve skin aesthetics, Ariessence™ Pure PDGF+ (www.ariessence.com), is available in leading innovative med/spa clinics and other aesthetic-focused offices, including dermatology and plastic surgery practices. Ariessence Pure PDGF+ is used topically to improve aesthetic outcomes associated with procedures such as micro-needling, dermabrasion, lasers, plastic surgery and other procedures in which healthier-looking skin can be accelerated and enhanced using growth factors such as PDGF.

“Growth factors play an important role in skin care today, but no other solutions are backed by the high level of scientific and clinical evidence that supports the safety and effectiveness of pure PDGF in multiple regenerative treatments,” said Lynch. “Ariessence Pure PDGF+ is based on this foundation of success in regenerative medicine.”

About Lynch Regenerative Medicine, LLC

Lynch Regenerative Medicine, LLC is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage and our decades-long commitment to safe and effective regenerative products of the highest quality to deliver exceptional results for our customers and their patients, thereby redefining the future of aesthetic regenerative medicine. The company was founded in 2023 and is based in Franklin, Tennessee.

Contacts

Nancy Rocco, n.rocco@lynchregen.com; 888-576-7343

Lynch Regenerative Medicine, LLC


Release Versions

Contacts

Nancy Rocco, n.rocco@lynchregen.com; 888-576-7343

More News From Lynch Regenerative Medicine, LLC

Lynch Regenerative Medicine Hires Hee as Chief Scientific Officer

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiaries LRM Aesthetics, Inc. (LRMA), and LRM WoundCare, Inc. (LRMW), announced today that Charlie Hee, Ph.D., will join its team as Chief Scientific Officer (CSO) across all companies, effective immediately. Dr. Hee is an experienced translational scientist and strategic leader, with more than 20 years of industry and research experience. Trained in tissue engineering, with a doctorate from the...

Lynch Regenerative Medicine Acquires REGRANEX® Gel and Exclusive Rights to Use Recombinant Pure PDGF for Soft Tissue Rejuvenation and Regeneration

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) announced today that it has acquired exclusive rights to REGRANEX® gel and recombinant purified platelet-derived growth factor (PDGF) from Smith & Nephew, Inc., for use in skin rejuvenation and regeneration as well as other soft tissue wound healing and tissue regeneration applications. PDGF is the first and only pure recombinant growth factor to have received approval from the U.S. Food and Drug Administration (FDA)...

Aesthetic Industry Leader Rob Hubert Announced as Chief Revenue Officer for Lynch Regenerative Medicine

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC., (LRM) and its wholly owned subsidiary LRM Aesthetics, Inc. (LRMA), announced today that Rob Hubert will serve as Chief Revenue Officer (CRO) across both companies, effective immediately. Hubert will report directly to Dr. Samuel Lynch, Founder and CEO of LRM. Hubert, who has served as a Strategic Advisor to LRM and LRMA for the past 18 months, brings more than 21 years of aesthetic business experience in sales and management....
Back to Newsroom